Abstract
Four novel platinum complexes, [Pt(en)]2ZL (1), [Pt(en)]2IPrBP (2), [Pt(en)]2MIBP (3) and [Pt(en)]2EIBP (4) [en = ethylenediamine; ZL = 1-hydroxy-3-(1H-imidazol-1-yl)ethane-1,1-diylbisphosphonic acid, commonly known as zoledronic acid; IPrBP = 1-hydroxy-3-(1H-imidazol-1-yl)propane-1,1-diylbisphosphonic acid; MIBP = 1-hydroxy-2-(2-methyl-1H-imidazol-1-yl)ethane-1,1-diylbisphosphonic acid; EIBP = 1-hydroxy-2-(2-ethyl-1H-imidazol-1-yl)ethane-1,1-diylbisphosphonic acid], were prepared and evaluated against five human cancer cell lines, including U2OS, A549, HCT116, MDA-MB-231 and HepG2. While exhibiting lower efficacy on the inhibition of cancer cell lines than cisplatin (CDDP), four complexes showed higher cytotoxicity than the corresponding ligands and relatively stronger cytotoxic effect on the hepatoma cell lines HepG2, and the complex 1 showed higher cytotoxicity than others on the whole. These complexes have better selectivity than the corresponding ligands in inhibiting hepatocarcinoma cells rather than normal liver cells, and the selective inhibitory effect of the complex 1 at the high concentration (100 μM) is better than that at the low concentration. Morphology studies exhibited typical characteristics of cell apoptosis and the cell cycle distribution analysis indicated that the complexes can inhibit cancer cells by inducing the cell cycle arrest at the G2/M phase, exhibiting a similar mechanism of action to CDDP. The binding interaction of complex with DNA has been explored by circular dichroism (CD) and UV–Vis absorption spectra, demonstrating these new complexes have moderate binding affinity for DNA.
Graphical Abstract
Four platinum complexes based on imidazolyl-containing bisphosphonates with effective antitumor activity and low hepatotoxicity were designed and evaluated.
Similar content being viewed by others
References
Loehrer PJ, Einhorn LH (1984) Ann Intern Med 100:704–713
Wong E, Giandomenico CM (1999) Chem Rev 99:2451–2466
Wheate NJ, Walker S, Craig GE, Oun R (2010) Dalton Trans 39:8113–8127
Rabik CA, Dolan ME (2007) Cancer Treat Rev 33:9–23
Heffeter P, Jungwirth U, Jakupec M, Hartinger C, Galanski M, Elbling L, Micksche M, Keppler B, Berger W (2008) Drug Resist. Update. 11:1–16
Chen A, Holt-Hindle P (2010) Chem Rev 110:3767–3804
Zhao J, Gou S, Liu F, Sun Y, Gao C (2013) Inorg Chem 52:8163–8170
Muhammad N, Guo Z (2014) Curr Opin Chem Biol 19:144–153
Ferri N, Facchetti G, Pellegrino S, Ricci C, Curigliano G, Pini E, Rimoldi I (2015) Bioorg Med Chem 23:2538–2547
Zutphen SV, Reedijk J (2005) Coord Chem Rev 249:2845–2853
Dancey JE, Chen HX (2006) Nat Rev Drug Discov 5:649–659
Strebhardt K, Ullrich A (2008) Nat Rev Cancer 8:473–480
Sanchez-Cano C, Hannon MJ (2009) Dalton Trans 48:10702–10711
Wang X, Guo Z (2013) Chem Soc Rev 42:202–224
Leu CT, Luegmayr E, Freedman LP, Rodan GA, Reszka AA (2006) Bone 38:628–636
Russell RGG (2011) Bone 49:2–19
Lipton A (2011) Expert Opin Pharmacol 12:749–762
Zhang S, Gangal G, Uludag H (2007) Chem Soc Rev 36:507–531
Torres Martin de Rosales R, Finucane C, Mather SJ, Blower PJ (2009) Chem Commun 32:4847–4849
Qiu L, Lin J, Cheng W, Wang Y, Luo S (2013) Med Chem Res 22:6154–6162
Ebetino FH, Hogan A-ML, Sun S, Tsoumpra MK, Duan X, Triffitt JT, Kwaasi AA, Dunford JE, Barnett BL, Oppermann U, Lundy MW, Boyde A, Kashemirov BA, McKenna CE, Russell RGG (2011) Bone 49:20–33
Widler L, Jaeggi KA, Glatt M, Muller K, Bachmann R, Bisping M, Born AR, Cortesi R, Guiglia G, Jeker H, Klein R, Ramseier U, Schmid J, Schreiber G, Seltenmeyer Y, Green JR (2002) J Med Chem 45:3721–3738
Margiotta N, Ostuni R, Teoli D, Morpurgo M, Realdon N, Palazzo B, Natile G (2007) Dalton Trans 29:3131–3139
Margiotta N, Capitelli F, Ostuni R, Natile G (2008) J Inorg Biochem 102:2078–2086
Margiotta N, Ostuni R, Gandin V, Marzano C, Piccinonna S, Natile G (2009) Dalton Trans 48:10904–10913
Xue Z, Lin M, Zhu J, Zhang J, Li Y, Guo Z (2010) Chem Commun 46:1212–1214
Piccinonna S, Margiotta N, Pacifico C, Lopalco A, Denora N, Fedi S, Corsini M, Natile G (2012) Dalton Trans 41:9689–9699
Lin J, Qiu L, Cheng W, Luo S, Ye W (2011) Nucl Med Biol 38:619–629
Pasini A, Caldiroia C, Spinelli S, Valsecchi M (1993) Synth React Inorg Met Org Chem 23:1021–1060
Rodan GA, Martin TJ (2000) Science 289:1508–1514
Langer R (2001) Science 293:58–59
Qiu L, Lin J, Wang L, Cheng W, Cao Y, Liu X, Luo S (2014) Aust J Chem 67:192–205
Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Osteoporosis Int 19:733–759
Iafisco M, Palazzo B, Marchetti M, Margiotta N, Ostuni R, Natile G, Morpurgo M, Gandin V, Marzano C, Roveri N (2009) J Mater Chem 19:8385–8392
Jamieson ER, Lippard SJ (1999) Chem Rev 99:2467–2498
Barton JK, Danishefsky A, Goldberg J (1984) J Am Chem Soc 106:2172–2176
Ivanov VI, Minchenkova LE, Schyolkina AK, Poletayev AI (1973) Biopolymers 12:89–110
Macquet JP, Butour JL (1978) Eur J Biochem 83:375–387
Takahara PM, Rosenzweig AC, Frederick CA, Lippard SJ (1995) Nature 377:649–652
Acknowledgments
The authors are grateful to the financial support from National Natural Science Foundation of China (21371082 and 21001055), Natural Science Foundation of Jiangsu Province (BK20141102 and BK20151118), Key Medical Talent Project of Jiangsu Province (RC2011097), Science Foundation of Health Department of Jiangsu Province (Q201204) and Public Service Platform for Science and Technology Infrastructure Construction Project of Jiangsu Province (BM2012066).
Author information
Authors and Affiliations
Corresponding authors
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Qiu, L., Lv, G., Cao, Y. et al. Synthesis and biological evaluation of novel platinum complexes of imidazolyl-containing bisphosphonates as potential anticancer agents. J Biol Inorg Chem 20, 1263–1275 (2015). https://doi.org/10.1007/s00775-015-1305-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00775-015-1305-z